Try our Advanced Search for more refined results

August 03, 2017

Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. December 12, 2023

    Novartis To Pay Daiichi $182M In Deal To End Appeal

    Novartis Pharmaceuticals has agreed to pay $182 million to Daiichi Sankyo subsidiary Plexxikon as part of a settlement in a patent infringement case over skin cancer drug Tafinlar after Novartis appealed a 2022 decision awarding Plexxikon $177.8 million, plus royalties.

12 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!